STAT13d
Roivant acquires drug for pulmonary hypertension from Bayer
Roivant executives believe that mosliciguat, administered once per day using a dry powder inhaler, will help fill "an unmet ...
FierceBiotech13d
Roivant unveils new ‘vant’ to take forward Bayer’s inhaled hypertension med
Matt Gline is back with a new ‘vant’ company, after the Roivant Sciences CEO paid Bayer $14 million upfront for the rights to ...
FiercePharma5d
Organon pays up to $1.2B to acquire Dermavant and its steroid-free skin cream Vtama
Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant for up to $1.2 billion, the companies announced ...
STAT13d
Pharmalittle: We’re reading about a Roivant deal, limited access to medicines and more
Top of the morning to you and a fine one it is. Blue skies, cool breezes and plenty of chirping birds are enveloping the ...
Strong Buy Rating for Roivant Sciences Backed by Strategic Dermavant Divestiture and Promising Clinical Pipeline
Goldman Sachs analyst Chris Shibutani has maintained their bullish stance on ROIV stock, giving a Buy rating today. Chris Shibutani has given ...
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...
BioSpace13d
Roivant Creates New ‘Vant’ to License Bayer’s Pulmonary Hypertension Drug
Under an in-license agreement worth up to $294 million, Roivant Sciences gains exclusive worldwide rights from Bayer to ...
Roivant creates Pulmovant to house lung disorder drug licensed from Bayer
Roivant (ROIV) announces Pulmovant, a new Vant member to develop lung disorder therapy mosliciguat, in licensed from Bayer ...